AN2728
BRAND NAME: none yet
GENERIC NAME: none yet
EXPERIMENTAL/INTERNAL COMPANY NAME: AN2728 |
|
| DRUG USE (P OR PsA) | METHOD OF DELIVERY | DEVELOPING COMPANY/COMPANIES |
| Plaque psoriasis | Topical | Anacor Pharmaceuticals, Inc. |
Description and Comments
AN2728 is an anti-inflammatory topical preparation (ointment) that inhibits TNF-alpha and the cytokines IL-12 and IL-23, the same molecules targeted by most of the currently available biologics. It is a conventional type of drug, not a biologic; also, it is not a steroid so it is unlikely to have the side effects that limit the use of topical steroids. Although it still has a long way to go in testing, the hope is that AN2728 might combine the efficacy of the biologics with the safety of a topical medication.
AN2728 is a phosphodiesterase-4 (PDE4) inhibitor. Other News and Links
Press release re Anacor Pharmaceuticals Proposed Initial Public Offering, 9/10/2010
Press release re AN2728 Phase 2b trial results, 6/15/2010
Information from the developer of AN2728, Anacor Pharmaceuticals, Inc. (2010)
